Human Papilloma Virus (HPV)

10 questions sur les vaccins et la vaccination

Les vaccins, c’est l’enfer ! Entre le carnet de vaccination perdu ou le médecin contacté en urgence qui ignore tout de notre situation, on ne sait plus vraiment où l’on en est dans notre calendrier de vaccins… Et si on mettait le nez dedans une bonne fois pour toute au lieu de laisser les choses s’enliser ?
Mon dernier vaccin date du collège, je dois faire lequel ?

More US girls now getting cervical cancer vaccine

More teen girls are getting a controversial cervical cancer vaccine but the increase isn't much of a bump, the government reported Thursday.
Last year's rise follows a couple of years when the girls' HPV vaccination rate was flat and health officials worried that it wouldn't budge. For girls ages 13 to 17, the rate is now up to about 38 percent of girls, from 33 percent.
"It was better than nothing. But we really need to do better moving forward," said Dr. Anne Schuchat of the Centers for Disease Control and Prevention.

HPV Vaccination Coverage Remains Unacceptably Low in the US

Human Papillomavirus (HPV), the leading cause of cervical cancer, is the most common sexually transmitted disease in the US. The virus comes in over 150 forms, and approximately 4 of these can be caught through direct skin-to-skin contact during all types of sex.
Some forms of the virus, such as HPV-6 and HPV-11, only cause minor conditions, such as genital warts. The highest risk forms of HPV however, HPV-16 and HPV-18, account for over 70% of cases of cervical cancer and over 5% of all cancer cases world wide.

HPV Vaccine Cleared Of Link To Blood Clotting

Study shows no link between HPV vaccine and Blood Clotting

Locally made vaccines ‘could boost immunisation efforts’

Mexico and South Africa want to start producing their own vaccines to boost their immunisation programmes, the 67th World Health Assembly (WHA) in Switzerland has heard.
The countries need the WHO and other international agencies to help expand their local manufacturing capacity, a move they hope will lower the cost of vaccines and make their supply more reliable.

Presentation: Strategies to supply high quality, affordable vaccines to emerging markets

At the last World Vaccine Congress Asia 2013, Xuefeng Yu of Tianjun Cansino Biotechnology gave the following presentation entitled: Strategies to supply high quality, affordable vaccines to emerging markets.
Some of the points covered in this presentation include:
  • Vaccine market status in developing countries
  • Current status to introduce new vaccine and improve quality of existing vaccines in developing countries
  • Challenges for developing country Manufactures (DCVMs)

Vaccinating Children Beyond the ‘Cold Chain’: Extending the Heat Stability of Vaccines

Shipping and storing vaccines in a ‘cold chain’ in the tropical heat of many resource-limited countries – whereby the vaccine is kept at temperatures between 2°C to 8°C from the point of manufacture until reaching the recipient – is a tremendous challenge and a major cause of poor immunisation coverage rates.

GAVI Alliance to present plans to expand impact of vaccines by 2020

As five African countries prepare to celebrate World Immunization Week (24-30 April) with the impending introduction of new vaccines, the GAVI Alliance is finalising plans to build on its successes with a major drive to increase access to vaccines and the impact of immunisation programmes by 2020.

Reduction in HPV in young women in England seen, following national immunization program

Each year around 2,000-2,500 women are diagnosed with cervical cancer in England, the most common cancer in women under 35. Infection with high-risk human papillomavirus (HR HPV) types 16 and 18 is responsible for around 70-80% of cervical cancers. A study conducted by Public Health England and presented today at the Society for General Microbiology's Annual Conference shows a reduction in these two HR HPV types – which are included in the HPV vaccines used – in sexually active young women in England.